The global castration-resistant prostate cancer (CRPC) treatment market is expected to garner a market value of USD 11.3 Billion in 2023 and is expected to accumulate a market value of USD 28 Billion by registering a CAGR of 9.5% in the forecast period 2023 to 2033. Growth of the castration-resistant prostate cancer (CRPC) treatment market can be attributed to increasing prevalence of the ailment and use of combination therapies to treat the ailment.
The market for castration-resistant prostate cancer (CRPC) treatment registered a CAGR of 6% in the historical period 2018 to 2022
Castration-resistant prostate cancer (CRPC) is a form of advanced prostate cancer that has become resistant to traditional hormone therapy (also known as androgen deprivation therapy or ADT). In CRPC, the cancer continues to grow despite low levels of testosterone in the body, which is typically the result of surgical or medical castration.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 11.3 Billion |
| Anticipated Forecast Value (2033) | USD 28 Billion |
| Projected Growth Rate (2023 to 2033) | 9.5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Castration-Resistant Prostate Cancer (CRPC) Treatment reflected a value of 6% during the historical period, 2018 to 2022.
Increasing prevalence of prostate cancer, the development of new therapies, and the rising demand for personalized medicine is driving the growth of the castration-resistant prostate cancer (CRPC) treatment market. Moreover, research and development along with technological integration for innovating medication is expected to bolster the demand for treatment of castration-resistant prostate cancer (CRPC) treatment market.
Thus, the market for Castration-Resistant Prostate Cancer (CRPC) Treatment is expected to register a CAGR of 9.5% in the forecast period 2023 to 2033.
Availability of diagnostic tools shaping landscape for CRPC market
The increasing incidence of prostate cancer, which is one of the most common cancers among men, is driving the demand for effective treatments for CRPC. The development of new treatment options, including targeted therapies, immunotherapies, and radiopharmaceuticals, has expanded the range of options available for the treatment of CRPC.
The aging population is more susceptible to prostate cancer and CRPC, and this demographic trend is increasing the demand for effective treatments for this disease. The availability of diagnostic tools such as imaging technologies, genomic testing, and liquid biopsies has improved the detection and monitoring of CRPC, which is contributing to the demand for effective treatments.
The increasing research and development activities in the field of oncology, including prostate cancer, are leading to the development of new and innovative treatments for CRPC. The government initiatives aimed at increasing awareness of prostate cancer and improving access to healthcare services are contributing to the growth of the CRPC treatment market.
Presence of different treatments creative lucrative opportunities for CRPC market
Second-line hormone therapy: This involves the use of different types of hormone therapy drugs that target different aspects of the androgen receptor pathway.
Chemotherapy: Chemotherapy drugs such as docetaxel and cabazitaxel may be used to treat CRPC.
Immunotherapy: Immune checkpoint inhibitors such as pembrolizumab and nivolumab have been approved for the treatment of certain types of CRPC.
Radiopharmaceutical therapy: Radiopharmaceuticals such as radium-223 and lutetium-177 PSMA have been approved for the treatment of CRPC that has spread to the bones.
Targeted therapy: Targeted drugs such as enzalutamide, abiraterone, and apalutamide may be used to treat CRPC by blocking specific pathways that fuel the growth of cancer cells.
Clinical trials: Participation in clinical trials of new treatments is also an option for some patients with CRPC.
Principal Consultant
Limited efficiency of treatments along with expensive nature of treatment affecting market growth
Many of the available treatment options for CRPC are expensive, and this can make them inaccessible to patients who cannot afford them or are not covered by health insurance. The side effects of many CRPC treatments, such as chemotherapy and immunotherapy, can be severe and impact a patient's quality of life. This can make it challenging for patients to tolerate the treatments and continue with their treatment plans.
While there are several treatment options available for CRPC, not all of them are effective for every patient. Some patients may not respond to certain treatments, and this can limit the efficacy of the available options. Some patients may develop resistance to the available treatments, which can make it challenging to manage their disease and prolong their survival.
Despite the advances in research and development, the underlying mechanisms of CRPC are not fully understood, and this can make it challenging to develop new and more effective treatments. Developing new treatments for CRPC can be challenging due to regulatory requirements, including the need for extensive clinical trials to demonstrate safety and efficacy. All these factors are derailing the growth of CRPC market.
Newer targeted therapies creating lucrative opportunities for CPRC treatment
The North American market for Castration-Resistant Prostate Cancer (CRPC) treatment is one of the largest markets in the world, due to the high prevalence of prostate cancer in the region and the availability of advanced healthcare infrastructure.
In terms of treatment options, chemotherapy and hormone therapy have been the mainstays of CRPC treatment in North America for many years, but newer targeted therapies such as abiraterone, enzalutamide, apalutamide, and radium-223 have also been approved for use. Immunotherapy, such as the use of immune checkpoint inhibitors, is also being investigated for CRPC treatment. Thus, North America is expected to possess 46% market share for castration-resistant prostate cancer (CRPC) treatment market in 2023.
Increasing awareness of diagnosis propelling demand for CRPC treatment in Europe
The Europe CRPC treatment market is being driven by the increasing prevalence of the disease in the region, as well as the growing awareness and diagnosis of the disease. In addition, the market is being driven by the introduction of novel treatments that offer better efficacy and fewer side effects than traditional therapies.
One of the most promising developments in CRPC treatment is the use of targeted therapies. These drugs are designed to specifically target the cancer cells and limit their growth and spread, while minimizing damage to healthy cells. Targeted therapies such as enzalutamide and abiraterone have shown significant benefits in treating CRPC, leading to their approval by regulatory agencies in Europe. Thus, Europe is expected to possess 40% market share for castration-resistant prostate cancer (CRPC) treatment market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Ease to administer oral medication increasing dependency to treat CRPC treatment
The oral route offers patients the convenience of taking medication in the comfort of their own homes. This is particularly beneficial for CRPC patients, who may need to take medication for extended periods of time. Oral medications can be taken without the need for hospital visits or invasive procedures, making treatment more accessible and less disruptive to a patient's daily life.
In addition, the oral route of administration can help to improve patient adherence to treatment. Patients are more likely to take their medication as prescribed when it is delivered in a convenient, easy-to-administer format. This is particularly important in the treatment of CRPC, where adherence to therapy is crucial for achieving positive treatment outcomes. Thus, by drug delivery method, oral route is expected to possess 55% market share for castration-resistant prostate cancer (CRPC) treatment market in 2023.
Key players in the castration-resistant prostate cancer (CRPC) treatment market are Sanofi S.A., Johnson and Johnson, Pfizer, Inc., Bayer AG, Abbott Laboratories, GlaxoSmithKline PLC, Northwest Biotherapeutics, Inc., Active Biotech AB, Astellas Pharma, Inc, Dendreon Corporation
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 11.3 Billion |
| Market Value in 2033 | USD 28 Billion |
| Growth Rate | CAGR of 9.5% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Therapy Type, Drug Class, Drug Delivery Method, Distribution Channel, Region |
| Regions Covered | North America; Latin America; Western Europe; Eastern Europe; APEJ; Japan; Middle East and Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Rest of Latin America, Germany, United Kingdom, France, Spain, Italy, Rest of Europe, India, Malaysia, Singapore, Thailand, Rest of South Asia, China, Japan, South Korea, Austria, New Zealand, GCC countries, South Africa, Israel, Rest of MEA |
| Key Companies Profiled | Sanofi S.A.; Johnson and Johnson; Pfizer, Inc.; Bayer AG; Abbott Laboratories; GlaxoSmithKline PLC; Northwest Biotherapeutics, Inc.; Active Biotech AB; Astellas Pharma, Inc; Dendreon Corporation |
| Customization | Available Upon Request |
The Asia Pacific region is projected to emerge as a lucrative market for Castration-Resistant Prostate Cancer (CRPC) Treatment.
The growth potential of the Castration-Resistant Prostate Cancer (CRPC) Treatment market is 8% through 2033.
The high cost of treatment is likely to limit market growth.
North America is likely to generate 46% revenue in 2023.
The global market size to reach USD 28 billion by 2033.
1. Executive Summary | Castration-Resistant Prostate Cancer (CRPC) Treatment Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy Type 5.1. Hormonal therapy 5.2. Chemotherapy 5.3. Immunotherapy 5.4. Radiotherapy 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 6.1. Antineoplastic 6.2. Non-steroidal Antiandrogen 6.3. Corticosteroids 6.4. Microtubule Inhibitor 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Delivery Method 7.1. Oral Route 7.2. Injectable Route 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 8.1. Hospital Pharmacies 8.2. Retail Pharmacies 8.3. Online Pharmacies 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. North America 9.2. Latin America 9.3. Europe 9.4. South Asia 9.5. East Asia 9.6. Oceania 9.7. MEA 10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 17. Key Countries Market Analysis 18. Market Structure Analysis 19. Competition Analysis 19.1. Sanofi S.A. 19.2. Johnson and Johnson 19.3. Pfizer, Inc. 19.4. Bayer AG 19.5. Abbott Laboratories 19.6. GlaxoSmithKline PLC 19.7. Northwest Biotherapeutics, Inc. 19.8. Active Biotech AB 19.9. Astellas Pharma, Inc. 19.10. Dendreon Corporation 20. Assumptions & Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Castration-Resistant Prostate Cancer (CRPC) Treatment Market
